Drug intelligence / Profile preview

schisantherin A

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral, Intragastric, Injection

Overview

Schisantherin A (STA) is a compound extracted from the traditional Chinese medicinal plant *Schisandra chinensis*. It possesses a range of pharmacological effects, including anti-inflammatory and antioxidant properties. Research indicates that Schisantherin A exhibits anti-hepatocellular carcinoma effects by significantly inhibiting the proliferation and migration of liver cancer cells in a concentration-dependent manner. Its mechanism of action involves regulating and inhibiting the glucose metabolism pathway, leading to anti-tumor effects observed both in vitro and in vivo in tumor xenograft models.

Beyond the preview

Go deeper on schisantherin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on schisantherin A.

Explore the full profile